IFPMA launches personalized CT web tool

11 February 2008

The International Federation of Pharmaceutical Manufacturers and Associations has upgraded its clinical trials portal (www.ifpma.org/clinicaltrials) to provide a personalized setting. The "MyPortal" feature allows users to record their own search criteria, simplifying searches on later visits to the web site and to request e-mail alerts when new trials are posted that match criteria they have specified.

The entire portal has been redesigned for greater clarity with explanations of technical jargon being provided in a user-friendly manner. Up to six searches may be stored by each user of the My Portal feature.

Harvey Bale, the IFPMA's director general, said: "patients, especially those with serious long-term conditions, have an interest to keep themselves informed about trials of new candidate medicines, as do their treating physicians. 'MyPortal' will make it easier for them to do so."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight